Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.43 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058394 | 0.91 | GPR119 (0.40) | GPR119NTRK1NR1H2HDAC6HDAC4 | |
| SCHEMBL612701 | 0.87 | GPR119 (0.51) | GPR119NTRK1HDAC6HDAC4RET | |
| SCHEMBL10058419 | 0.86 | GPR119 (0.39) | GPR119 | |
| SCHEMBL609800 | 0.84 | GPR119 (0.36) | GPR119NTRK1NR1H2F2R | |
| SCHEMBL609801 | 0.84 | GPR119 (0.36) | GPR119NTRK1NR1H2F2R | |
| SCHEMBL10058415 | 0.80 | GPR119 (0.47) | GPR119 | |
| SCHEMBL612024 | 0.80 | GPR119 (0.39) | GPR119 | |
| SCHEMBL612843 | 0.79 | GPR119 (0.35) | GPR119BACE1BACE2NTRK1NR1H2 | |
| SCHEMBL610917 | 0.79 | GPR119 (0.47) | GPR119BACE1BACE2HDAC6HDAC4 | |
| SCHEMBL609508 | 0.77 | GPR119 (0.39) | GPR119NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040953-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, GPR132, FFAR2 | GPR119 1/4885BACE1 3825/4885BACE2 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.